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Abstract
Mastermind-like 1 (MAML1) is a transcriptional coregulator of activators in various signaling pathways, such as Notch, p53,
myocyte enhancer factor 2C (MEF2C) and beta-catenin. In earlier studies, we demonstrated that MAML1 enhanced p300
acetyltransferase activity, which increased the acetylation of Notch by p300. In this study, we show that MAML1 strongly
induced acetylation of the transcription factor early growth response-1 (EGR1) by p300, and increased EGR1 protein
expression in embryonic kidney cells. EGR1 mRNA transcripts were also upregulated in the presence of MAML1. We show
that MAML1 physically interacted with, and acted cooperatively with EGR1 to increase transcriptional activity of the EGR1
and p300 promoters, which both contain EGR1 binding sites. Bioinformatics assessment revealed a correlation between
p300, EGR1 and MAML1 copy number and mRNA alterations in renal clear cell carcinoma and p300, EGR1 and MAML1 gene
alterations were associated with increased overall survival. Our findings suggest MAML1 may be a component of the
transcriptional networks which regulate EGR1 target genes during nephrogenesis and could also have implications for the
development of renal cell carcinoma.
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Introduction
Mastermind-like 1 (MAML1) is the human homolog of
Drosophila Mastermind, a neurogenic gene genetically linked to
Notch function [1,2]. The Notch signaling pathway plays an
important role in many developmental processes by influencing
cellular proliferation, differentiation and apoptosis. In the nucleus,
the Notch intracellular domain (Notch ICD) associates with the
transcription factor CSL (also known as RBP-Jk or CBF1 in
vertebrates, Suppressor of Hairless in Drosophila and Lag-1 in C.
elegans) when it is bound to DNA, and coactivators such as PCAF
[3], GCN5 [3], p300 [4] and MAML1 [1,2] are recruited to
activate the expression of Notch target genes. Recently, MAML1
has been shown to function as a coactivator for transcription
factors involved in a variety of Notch-independent signaling
pathways, including myocyte enhancer factor 2C (MEF2C) [5],
p53 [6] and beta-catenin [7], and the N-terminus of MAML1 is
crucial for these interactions. These findings suggest that MAML1
functions as a coactivator in diverse cellular processes and may be
a mediator of crosstalk between different signaling pathways.
MAML1 may also affect various signaling pathways by interacting
with p300, a commonly used coactivator. We and other
researchers have previously reported that MAML1 mediates
Notch ICD-mediated transcription in vivo, and can also form
chromatin templates in vitro, by recruiting p300 to a DNA-CSL-
Notch complex [8,9,10]. We recently reported that MAML1
enhances p300 autoacetylation, histone acetyltransferase (HAT)
activity and coactivator function [11]. We also found that p300
acetylates the Notch1 ICD in cell culture assays and in vitro, and
that regions located within the Notch C-terminus are essential for
Notch acetylation. MAML1 and CSL, components of the Notch
transcription complex, strongly enhance Notch acetylation and we
suggested that MAML1 increases Notch acetylation by potentiat-
ing p300 autoacetylation [12]. p300 can also acetylate MAML1,
although the effect of this posttranslational modification on the
function of MAML1 is currently unknown. MAML1 is a
phosphoprotein, and we previously identified GSK3ß as one
kinase responsible for phosphorylation of MAML1 in vitro [13].
The active form of GSK3ß directly interacts with the N-terminus
of MAML1 to inhibit MAML1 transcriptional activity [13]. In
addition, the MAML1 N-terminus is subject to SUMOylation,
which also represses the transcriptional activity of MAML1 [14].
The transcription factor early growth response-1 (EGR1) is
expressed in response to various extracellular signals, such as
growth factors, cytokines, irradiation, and various kinds of stress.
In many normal cells, growth factor stimulation rapidly induces
expression of EGR1, which subsequently leads to the activation of
downstream growth pathways [15]. However, EGR1 can also
suppress growth when overexpressed in transformed cells in
several experimental systems [16]. The cellular response to EGR1
with respect to apoptosis varies: EGR1 can induce apoptosis by
stimulating either p53 or PTEN; however, EGR1 can also
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promote survival in certain cell types by counteracting p53-
dependent apoptosis [17]. EGR1 plays an important role as a
tumor suppressor in breast, brain and lung cancer, as EGR1 is
poorly expressed in these tissues and acts as a suppressor of growth
and transformation when overexpressed [16]. In contrast,
expression of EGR1 appears to be maintained in a high
proportion of prostate and kidney cancers, where it promotes
growth. EGR1 is absent or expressed at low levels in normal
prostate tissues; whereas the EGR1 promoter is regulated by a
positive feedback loop between EGR1 and growth factors in
prostate cancer cells, which results in constitutive growth. Prostate
cancer tissues also express high levels of p300, which leads to
constitutively high levels of stable acetylated EGR1 protein, which
is an important component in the transformation and progression
of this disease [18]. The levels of EGR1 increase with the degree of
malignancy in prostate cancer, as indicated by the Gleason tumor
score [15]. The ability to reduce EGR1 expression may provide an
efficient clinical treatment for prostate cancer, as downregulation
of EGR1 may reduce growth factor induction and positive
feedback to the EGF1 promoter.
EGR1 has been implicated as an important factor in
nephrogenesis and the development of renal cancer. During
embryogenesis, EGR1 is expressed in almost all proliferating cells
including metanephric blastems; however, it is normally down-
regulated during renal development [19]. Expression of EGR1 is
also elevated in many Wilms’ tumors compared to normal kidney
tissues. Wilms’ tumor is a pediatric malignancy of the kidney,
which is often of embryonic origin [20]. Overexpression of EGR1
has been reported to increase proliferation, enhance tumor growth
and antagonize the effects of the tumor suppressor Wilms tumor 1
(WT1) in baby rat kidney cells [21]. Renal cell carcinoma (RCC) is
the most common kidney cancer in adults, accounting for 80–85%
of primary kidney malignances. Clear cell (conventional) RCC and
renal papillary cell carcinoma are the most and second-most
frequent types of RCC, respectively. Strefford and colleagues
reported that chromosome 5 was overrepresented and rearranged
in a significant proportion of 19 renal cell carcinoma cell lines,
with the genes encoding EGR1 (5q31.1) and CSF1R (Colony-
stimulating factor 1 receptor) (5q33–q35) most frequently altered
on chromosome 5, further supporting a role for EGR1 in renal
cancer [22]. In a previous study, we reported that MAML1
increased p300 autoacetylation and p300 acetylation activity in
embryonic kidney (HEK293) cells [11]. The objective of the
present study was to investigate whether MAML1 and p300
regulate the levels of EGR1 in kidney cells.
Materials and Methods
Plasmids
pcDNA3.1-FLAG-EGR1 and pGL3-p300 were purchased from
Addgene (Cambridge, MA, USA). The plasmid 4xEBS1-luc was a
kind gift from Dr. G. Thiel (University of Saarland Medical
Center, Homburg, Germany) and pGl3-EGR1 was generously
provided by Dr. T.E. Eling (National Institute of Environmental
Health Sciences, NC, USA). pcDNA3.1-FLAG-MAML1 (1–
1016), (1–625) and cmv-p300-HA have been described previously
[11]. The cDNA encoding MAML1 (1–127) and (75–1016) were
amplified by PCR and subcloned into the expression vector
FLAG-pcDNA3.1.
Cell lines
The MAML1 cell lines were constructed by transfecting human
embryonic kidney (HEK)-293 cells with the vectors pcDNA3.1-
FLAG-MAML1 or pcDNA3.1-MAML1 and stable clones were
selected with geneticin [11].
siRNA transfection
HEK-293 cells were transiently transfected with 100 nM
MAML1 siRNA (predesigned MAML1 SMARTpool set of 4
siRNAs; Dharmacon) or control siRNA using DharmaFECT 1
siRNA reagents (Dharmacon, Lafayette Colorado, USA), and
cultured in the presence or absence of 50 ng/ml TPA (12-O-
Tetradecanoylphorbol-13-Acetate) (Cell Signaling Technology,
Boston, MA, USA).
Reporter gene assay
HEK-293 cells in 24-well plates were transiently transfected
using TransIT-LT1 reagent (Mirus, Madison, WI, USA) with
200 ng reporter plasmid DNA and 150 ng EGR1 or MAML1
expression vector DNA, as indicated in the figures. The cells were
lysed in Reporter Lysis buffer (Promega, Madison, WI, USA) after
24 h and luciferase activity was measured using LucySoft3. The
data are reported as the mean values of at least three independent
experiments.
Real-time PCR
Total RNA was purified using the RNeasy mini kit (Qiagen,
Hilden, Germany) according to the manufacturer’s protocol and
cDNA was synthesized using the Superscript III first-strand
synthesis system (Invitrogen, Carlsbad, CA, USA). Real-time
PCR was performed using Power SYBR Green master mix
(Applied Biosystems, Foster City, CA, USA) on an Applied
Biosystems 7500 Sequence detector using the following primers
sets: EGR1 forward, 59-TACGAGCACCTGACCGCAG-39;
reverse, 59-CACCAGCACCTTCTCGTTGTT-39;
18S rRNA forward, 59-CCTGCGGCTTTAATTTGACTCA-
39;
reverse, 59-AGCTATCAATCTGTCAATCCTGTC-39.
EGR1 mRNA expression was normalized to 18S rRNA in each
sample.
In vivo acetylation assay
HEK-293 cells were transiently transfected with pcDNA3.1-
FLAG-EGR1, pcDNA3.1-MAML1 and cmv-p300-HA using
TransIT-LT1 transfection reagent (Mirus, Madison, WI, USA).
After 24 h, the cells were treated with 10 mM sodium butyrate.
The cells were harvested 40 h after transfection, lysed in lysis
buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% Triton X-100
and complete EDTA-free protease inhibitor Pierce). Immunopre-
cipitation of FLAG-EGR1 was performed using M2-agarose that
recognizes the FLAG epitope. The input and immunoprecipita-
tion (IP) samples were analyzed by Western blotting using the
following antibodies: EGR1 (Santa Cruz Biotechnology, CA,
USA), the acetylated lysines in EGR1 (Cell Signaling Technology,
Boston, MA, USA), p300 (Santa Cruz Biotechnology, CA, USA),
MAML1 (Bethyl Laboratories, Cambridge, United Kingdom;
Millipore, Billerica, MA, USA) and acetylated p300 lysine 1499
(Cell Signaling Technology, Boston, MA, USA).
Co-immunoprecipitation
Whole-cell lysates from HEK-293 cells were pre-cleared and
endogenous MAML1 was immunoprecipitated using an MAML1
antibody (Santa Cruz Biotechnology, CA, USA). The input and IP
samples were analyzed by Western blotting using the following
antibodies: MAML1 (Bethyl laboratories, Cambridge, United
Kingdom) and EGR1 (Santa Cruz Biotechnology, CA, USA).
EGR1/p300/MAML1 Transcription Complex
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Immunostaining
HCT116 cells were transfected with pcDNA3-FLAG-EGR1
and pcDNA3.1-MAML1 using TransIT-LT1 transfection reagent
(Mirus, Madison, WI, USA), incubated for 24 h, washed with
PBS, fixed with 4% paraformaldehyde, and permeabilized with
0.5% Triton X-100 (Sigma-Aldrich, St. Louis, Missouri, USA).
The cells were immunostained using FLAG (Sigma-Aldrich, St.
Louis, Missouri, USA) and MAML1 (Millipore, Billerica, MA,
USA) antibodies, and analyzed using a Leica confocal microscopy
(Leica Microsystems, Wetzler, Germany).
GST pull-down assay
HEK293 cells were transfected with pcDNA3.1-FLAG-EGR1
using TransIT-LT1 transfection reagent, and cultured for 2 h with
50 ng/ml TPA 24 h post-transfection. Whole cell lysates were
prepared and 100 ml aliquots of protein extract in lysis buffer
(50 mM Tris-HCl pH 8, 150 mM NaCl, 1% Triton X-100,
1 mM DTT and 16 complete EDTA-free protease inhibitor
cocktail) were incubated with GST proteins (prepared as described
in [14]) bound to Glutathione Sepharose 4B beads (GE
Healthcare, Little Chalford, United Kingdom) in BC-150 buffer
(50 mM Tris-HCl pH 7.5, 150 mM KCl, 10% glycerol) overnight
at 4uC. After washing with BC-150 buffer, the bound proteins
were eluted in SDS-PAGE loading buffer (1 M Tris-HCl pH 6.8,
50% glycerol, 10% SDS, 1% bromophenol blue, 1 mM DTT),
separated using 7.5% SDS-polyacrylamide gels, transferred to
PVDF membranes (GE Healthcare, Little Chalford, United
Kingdom) and incubated with an antibody recognizing EGR1
(Santa Cruz Biotechnology, CA, USA).
Protein stability assay
HEK-293 FLAG-MAML1 and HEK-293 control cells were
cultured in 24-well plates and treated with 50 ng/ml TPA for 2 h
and 50 mg/ml cyclohexamide (Sigma-Aldrich, St. Louis, Missouri,
USA) for 1 h. The cells were harvested in lysis buffer (50 mM
Tris-HCl pH 8, 150 mM NaCl, 1% Triton X-100 and complete
EDTA-free protease inhibitor cocktail), the proteins were sepa-
rated using SDS-PAGE and subjected to immunoblotting using an
antibody recognizing EGR1 (Santa Cruz Biotechnology, CA,
USA). The intensities of the bands were quantified with Image J
(rsb.info.nih.gov/ij/index.html).
Bioinformatic analysis of MAML1, EGR1 and p300
Expression of MAML1, EGR1 and p300 were analyzed in tumor
samples from 20 different cancer studies using the web-based cBio
Cancer Genomics Portal (http://www.cbioportal.org/, last ac-
cessed 07/26/12) including genomics data, e.g., DNA copy
number data from 5134 samples (array-comparative genomic
hybridization) and mRNA expression data from 2430 samples
(RNA-sequencing). Putative copy number alterations such as
amplifications and homozygous deletions were derived within the
portal using the ‘‘genomic identification of significant targets in
cancer’’ algorithm [23]. The mRNA expression changes were
considered significant if samples displayed a Z-score $2 compared
to the reference population (diploid tumors or normal adjacent
tissues if applicable). The association of altered gene expression
with overall survival was assessed in selected cancer studies using
Kaplan-Meier analysis. The patient samples were divided into two
groups based on ‘‘gene set altered’’ or ‘‘gene set not altered’’ using
the selected genomics data, and significant survival differences
between the groups were determined using the log-rank test; p-
values ,0.05 were considered statistically significant.
Results and Discussion
MAML1 regulates EGR1 mRNA and protein expression
EGR1 protein stability has been reported to be stabilized by
p300 acetylation, which results in the transactivation of survival
genes [18]. As we previously found that MAML1 increases p300
autoacetylation, which enhanced the acetylation activity of p300
[11], we set out to investigate whether EGR1 expression levels
could be elevated by MAML1. First, we transfected embryonic
kidney (HEK-293) cells with MAML1 siRNA or control (Ctrl)
siRNA, and cultured the cells in the presence of TPA to induce
expression of EGR1. The proteins were detected by immunoblot-
ting with antibodies recognizing MAML1, EGR1 and GAPDH.
Expression of EGR1 was induced in cells cultured with TPA
(Figure 1A, lanes 3 and 4); whereas the levels of EGR1 were
reduced in cells treated with MAML1 siRNA (lane 4), compared to
cells treated with control siRNA (lane 3). Next, we prepared whole
cell extracts from HEK-293 cells stably expressing MAML1 and
control HEK-293 cells, after inducing expression of EGR1 with
TPA. The proteins were detected by immunoblotting with
antibodies recognizing MAML1, EGR1 and GAPDH. As shown
in Figure 1B, EGR1 was induced by TPA (lanes 2 and 4) and the
expression of EGR1 significantly increased in cells overexpressing
MAML1 (lane 4). Next, we investigated whether MAML1 affected
EGR1 mRNA levels. HEK-293 cells were transfected with
MAML1 siRNA or control siRNA, cultured with TPA for 2 hours,
and EGR1 mRNA expression was analyzed by real-time RT-PCR.
Transfection of HEK-293 cells with MAML1 siRNA significantly
reduced the expression of EGR1 mRNA, compared to cells
transfected with control siRNA (Figure 1C). In agreement with this
observation, EGR1 mRNA increased in the MAML1-expressing
cell line after induction with TPA, compared to control HEK-293
cells (Figure 1D). Thus, our data suggested that MAML1 might be
involved in the regulation of EGR1 mRNA and protein expression
in embryonic kidney cells.
EGR1 has a distinct spatio-temporal expression pattern during
nephrogenesis [19], and disturbances in the regulation of EGR1
protein expression can lead to unwanted effects on normal cell
fate. Overexpression of EGR1 has been reported to increase the
proliferation of kidney cells and enhance tumorigenesis [21].
Therefore, proteins affecting the expression of EGR1, such as
MAML1, might ultimately be connected to the EGR1 signaling
pathway, which determines cell fate.
MAML1 physically interacts with EGR1
We next investigated whether MAML1 could induce expression
of an EGR1 target promoter, by transfecting the 4xEBS-luc
reporter containing four EGR1 binding sites into cells expressing
FLAG-MAML1 and control HEK-293 cells, and culturing the
cells with TPA. The reporter activity increased when EGR1 was
induced in control cells using TPA; however, the reporter activity
was enhanced almost three fold in FLAG-MAML1 cells cultured
with TPA, compared to control cells cultured with TPA
(Figure 2A). In addition, HEK-293 cells were co-transfected with
4xEBS-luc and vectors expressing EGR1 and/or MAML1. While
both EGR1 and MAML1 increased the activity of the EGR1
promoter; together EGR1 and MAML1 synergistically induced a
500-fold increase in the activity of the EGR1 target promoter
(Figure 2B). Thus, our data suggest MAML1 may be recruited to
promoters regulated by EGR1, to increase expression of the genes
regulated by EGR1.
To elucidate if MAML1 interacts with EGR1, whole-cell
extracts were prepared from HEK-293 cells and MAML1 was
immunoprecipitated using an antibody recognizing MAML1. The
EGR1/p300/MAML1 Transcription Complex
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proteins were separated by SDS-PAGE and Western blotting was
performed using antibodies recognizing MAML1 and EGR1. As
shown in Figure 2C, MAML1 and EGR1 interacted in the cellular
extracts (lane 3). To determine whether EGR1 colocalized with
MAML1, HCT116 cells were co-transfected with FLAG-EGR1
and MAML1 vectors and immunostained with antibodies
recognizing FLAG and MAML1. EGR1 and MAML1 were
strongly colocalized in the nucleus (Figure 2D). We noticed that
the expression pattern of EGR1 in the nucleus changed in the
presence of MAML1. We, and others, have previously reported
that MAML1 colocalize MAML1-interacting proteins to nuclear
bodies [24]. Our data suggest that EGR1 and MAML1 may form
part of a transcription enhancer complex, which can increase the
expression of genes with EGR1 binding sites. Both MAML1 and
EGR1 are endogenously expressed in embryonic kidney cells, and
both of these transcription factors have been shown to regulate
gene expression during developmental processes [25,26]; however,
it remains to be elucidated whether MAML1 and EGR1
cooperate to regulate any of these genes.
MAML1 and EGR1 synergistically activate the p300
promoter
The p300 promoter has been reported to contain EGR1
binding sites and to be regulated by EGR1 [18]. Therefore, we co-
transfected HEK-293 cells with a p300-luc reporter and vectors
expressing EGR1 and MAML1, and then cultured the cells in the
presence of TPA. EGR1 alone activated the p300-luc reporter in
the presence of TPA, and co-transfection of MAML1 with EGR1
strongly increased the activity of the p300 reporter (Figure 3A). We
hypothesized that MAML1 may regulate the expression of p300,
as well as the acetylation activity of p300 [11]. Lysates were
prepared from a FLAG-MAML1 cell line and HEK-293 control
cells, and the levels of p300 were analyzed by Western blotting
using an antibody recognizing p300. The expression of p300
increased in the MAML1-expressing cell line, compared to control
cells (Figure 3B, compare lane 2); whereas the expression level of
GAPDH, which is not a MAML1 target, was similar in both cell
lines (lanes 1 and 2).
EGR1 is a substrate for acetylation by p300 [18], and we have
previously shown that MAML1 regulates p300 activity by
increasing p300 autoacetylation [11]. Therefore, we investigated
whether MAML1 regulates p300-dependent acetylation of EGR1.
Figure 1. MAML1 regulates EGR1 mRNA and protein expression. (A) HEK-293 cells were transfected with MAML1 siRNA or control (Ctrl)
siRNA, and cultured in the presence of TPA to induce expression of EGR1. Proteins were detected by immunoblotting using antibodies recognizing
MAML1, EGR1 and GAPDH. (B) Whole cell extracts were prepared from cells expressing MAML1 and control HEK-293 cells cultured with TPA. Proteins
were detected by immunoblotting using the indicated antibodies. (C) HEK-293 cells were transfected with MAML1 siRNA or control siRNA, cultured
with TPA; then EGR1 mRNA expression was analyzed by real-time PCR. (D) HEK-293 control cells and HEK-293 cells stably expressing FLAG-MAML1
were cultured with TPA; then EGR1mRNA expression was analyzed by real time PCR. The data is presented as the mean6 standard error of the mean
(SEM) and expressed relative to EGR1 levels in control HEK-293 cells cultured in the absence of TPA.
doi:10.1371/journal.pone.0046001.g001
EGR1/p300/MAML1 Transcription Complex
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Whole-cell extracts were prepared from HEK-293 cells and EGR1
was immunoprecipitated using an antibody recognizing EGR1.
The proteins were separated by SDS-PAGE and Western blotting
was performed using antibodies recognizing EGR1, the acetylated
lysines in EGR1, MAML1, p300 and the acetylated lysine at 1499
of p300 (a marker of p300 autoacetylation). We noticed that
expression of EGR1 increased in the presence of co-expressed
MAML1 and/or p300 (Figure 3C, compare lane 1 to lanes 2–4).
However, we only detected acetylated EGR1 in the presence of
co-expressed p300 (lanes 3 and 4), which strongly increased in the
presence of MAML1 (lane 4). The increased expression of EGR1
protein in the presence of co-expressed MAML1 (lane 2) might be
due to MAML1-dependent up-regulation of EGR1 mRNA (see
Figure 1). In agreement with our earlier observations, p300
autoacetylation was significantly increased by MAML1 (compare
lanes 3 and 4). Thus, we presume that autoacetylated p300
acetylates EGR1 more efficiently.
Numerous reports have described how acetylation may increase
protein stability [27]. Therefore, we induced expression of EGR1
using TPA in cells stably expressing MAML1 and HEK-293
control cells. After 1 h incubation with cyclohexamide, signifi-
cantly more EGR1 protein was present in the MAML1-expressing
cell line compared to control cells (Figure 3D). Thus, we suggest
that MAML1 may be involved in regulating the stability of EGR1,
possibly by increasing the acetylation of EGR1. Acetylation of
EGR1 by p300 has been reported to increase the protein levels of
EGR1, to stimulate expression of cell growth and survival genes
such as FGF2, PDGFB, TGFB1 and IGF2, and hence plays a
crucial role in prostate cancer [15,18]. As EGR1 is expressed at
high levels in prostate cancer and also certain renal cancers
[21,22], it remains to be investigated whether p300-dependent
acetylation of EGR1 affects the expression of EGR1 target genes
or plays a role in the development of renal cancer.
The N-terminus of MAML1 cooperates with EGR1 during
transcriptional activation
The MAML1 protein contains various domains, which are
important for protein interactions and the function of MAML1
(see schematic in Figure 4A). Amino acids 1–74 of MAML1
Figure 2. MAML1 physically and functionally interacts with EGR1. (A) FLAG-MAML1 expressing cells and HEK-293 control cells were
transfected with a luciferase reporter containing four EGR1 binding sites (4xEBS-luc) and cultured with TPA to induce expression of EGR1. The data is
presented as mean6 SD. (B) HEK-293 cells were co-transfected with 4xEBS-luc and vectors expressing EGR1 and MAML1. (C) Whole-cell extracts were
prepared from HEK-293 cells and MAML1 protein was immunoprecipitated using an antibody recognizing MAML1. The proteins were separated by
SDS-PAGE and analyzed by Western blotting using antibodies recognizing MAML1 and EGR1. (D) Vectors expressing FLAG-EGR1 and MAML1 were
co-transfected into HCT116 cells; after 24 h the cells were immunostained using the indicated antibodies and analyzed by confocal microscopy with
1006 oil lens.
doi:10.1371/journal.pone.0046001.g002
EGR1/p300/MAML1 Transcription Complex
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interact with the Notch ICD and MEF2C, while amino acids 75–
305 are important for the interaction with p300. The N-terminal
domain of MAML1 also interacts with p53 and GSK3ß [24]. To
investigate which MAML1 domain is required for activation of the
promoters regulated by EGR1, plasmids expressing EGR1 and
various MAML1 domains were co-transfected with the 4xEBS-luc
reporter, which contains four EGR1 binding sites, into HEK-293
cells. As shown in Figure 4B, MAML1(1–1016) and (75–1016)
strongly enhanced luciferase reporter gene activity in the presence
of EGR1, while MAML1(1–625) had no detectable effect on
EGR1-promoter activation. MAML1 (1–1016) and (75–1016)
were expressed at similar levels in the cell culture assay, while we
detected higher levels of MAML1(1–625) (Figure 4C).
In order to examine which region of MAML1 interacts with
EGR1, full-length GST-tagged MAML1 protein and MAML1
derivatives (Figure 4D) were incubated with whole cell extracts
from HEK293 cells transfected with EGR1. EGR1 interacted
strongly with full-length GST-MAML1 protein and MAML1(1–
300); but only showed a week interaction with MAML1 (1–625)
and (309–625) (Figure 4E). Since we detected a strong EGR1-
interaction especially with MAML1(1–300), we further investigat-
ed the role of the N-terminus MAML1 in EGR1 transcription by
co-transfecting HEK-293 cells with the 4xEBS-luc reporter and
plasmids expressing EGR1, MAML1 full-length and MAML1(1–
127). As shown in Figure 4F, MAML1(1–127) repressed the
MAML1-EGR1 synergistic activation of the EGR1-promoter. We
conclude that a domain within amino acids 75–127 of MAML1
may be important for the synergistic effect of MAML1 and EGR1
on gene transcription. The MAML1 N-terminus is reported to
interact with Notch, MEF2C, p53 and GSK3beta, and to play an
important role in the transcriptional activity of these factors
[1,2,5,6,13]. The N-terminal domain of MAML1 is also required
for the interaction of MAML1 with p300, which leads to increased
p300 autoacetylation and HAT activity [12]. In addition, MAML1
contains two N-terminal SUMOylation sites (K217 and K299)
which repress MAML1 activity [14]. Therefore, the interactions of
Figure 3. Activity of the p300 promoter is increased by MAML1. (A) HEK-293 cells were co-transfected with a p300-luc reporter, EGR1 and
MAML1, then cultured in the presence of TPA to induce expression of EGR1. The data is presented as mean 6 SD. (B) Whole cell extracts were
prepared from FLAG-MAML1 transfected and control HEK-293 cells (Ctrl) and MAML1, p300 and GAPDH were detected by Western blotting. (C)
Whole-cell extracts were prepared from HEK-293 cells transfected with vectors expressing FLAG-EGR, MAML1 and p300; FLAG-EGR1 was
immunoprecipitated using an antibody recognizing the FLAG epitope. The proteins were separated by SDS-PAGE and detected by Western blotting
using antibodies recognizing EGR1, acetylated lysines in EGR1, MAML1, p300 and acetylated lysine1499 of p300. (D) HEK-293 cells stably expressing
FLAG-MAML1 and HEK-293 control cells were cultured with TPA (2 h) in the presence or absence of cyclohexamide (1) and EGR1 protein expression
was analyzed by Western blotting using an antibody recognizing EGR1. In the graph, EGR1 protein expression in the MAML1 stable cell line is
expressed relative to control cells treated with cyclohexamide. The ratio of band intensities before the addition of cycloheximide and after 1 h of
treatment with cycloheximide was determined with Image J.
doi:10.1371/journal.pone.0046001.g003
EGR1/p300/MAML1 Transcription Complex
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MAML1 should be further investigated, in order to determine
whether the interaction of EGR1 with MAML1 occurs in
competition, or perhaps in synergy, with other transcription
factors such as Notch and p53.
MAML1 positively correlates with EGR1 and p300 in
kidney cancer
Based on the strong mechanistic evidence presented for co-
regulation between MAML1, EGR1 and p300, we assessed a
genomics database for such relationship. Our bioinformatic
analysis of copy-number alterations (including amplifications and
homozygous deletions) in the MAML1, EGR1 and p300 gene set
revealed alterations in 18 of the 20 cancer studies assessed
(Figure 5A). The highest level of alteration for the gene set was
observed in renal clear cell carcinoma patients (7%) and renal
papillary cell carcinoma patients (4%). Around 3% of the liver
hepatocellular carcinoma and serous ovarian carcinoma patients
displayed copy-number alterations for the gene set, while the other
14 cancer types showed alterations around 2% or below
(Figure 5A). In contrast, no significant alterations were seen for
pancreatic and prostate adenocarcinoma. Further analyses of the
copy number changes in renal clear cell carcinoma showed that
MAML1 was amplified in 7% of the samples and EGR1 was
amplified in 5% of the samples (Figure 5B).MAML1 and EGR1 co-
amplifications were observed in 61% of the samples from patients
with either MAML1 or EGR1 amplification (data not shown).
Analysis of the mRNA expression levels extracted from the
Cancer Genomics Portal (see Materials and Methods) indicated
increased expression of MAML1, EGR1 and p300 in 5%, 7% and
4% of the renal clear cell carcinoma samples, respectively
(Figure 5C). However, reduced expression of MAML1 and p300
were noted in 2% and 1% of the renal clear cell carcinoma
samples, respectively. Expression changes in two or more genes
from the MAML1, EGR1 and p300 gene set was observed in
approximately 19% of the renal clear cell carcinoma samples (data
not shown). The association between altered expression of the
gene set at the mRNA level and overall survival in renal clear cell
carcinoma was assessed. Kaplan-Meier analysis of the group of 69
patients with differential expression of at least one gene from the
gene set (gene set altered) and the group of 349 patients with no
Figure 4. The N-terminus of MAML1 acts synergistically with EGR1 to activate transcription of EGR1-target genes. (A) Schematic
illustration of the MAML1 domains. (B) HEK-293 cells were co-transfected with 4xEBS-luc and vectors expressing EGR1, MAML1 and truncations of
MAML1, as indicated in the figure. The data is presented as mean 6 SD. (C) Western blots showing the expression levels of MAML1 full-length and
mutant proteins in HEK-293 cells. (D) PageBlue Protein-stained SDS-gel showing migration of the purified GST-tagged MAML1 proteins used for
protein-protein interaction assay. (E) GST-tagged MAML1 derivatives and GST coupled to glutathione-Sepharose beads were incubated with HEK-293
whole cell extracts, and MAML1-interacting EGR1 was detected by immunoblotting. The input represents 2% of the whole cell extract used in the
binding reaction. (F) HEK-293 cells were co-transfected with 4xEBS-luc and vectors expressing EGR1, MAML1 (1–1016) and (1–127). The data is
presented as mean 6 SD.
doi:10.1371/journal.pone.0046001.g004
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alterations (gene set not altered) reveled altered gene expression
had a significant impact on overall survival (Figure 5D). Alter-
ations in the gene set were associated with increased overall
survival in renal clear cell carcinoma (p=0.000356) compared to
the unaltered gene set. Similar analysis revealed that copy-number
alterations had no significant effect on overall survival (data not
shown).
In conclusion, we provide evidence that the transcriptional
coactivator MAML1 acts cooperatively with EGR1 to increase
transcriptional activity of the EGR1 and p300 promoters in
embryonic kidney cells. Moreover, using public data sets we have
determined that alterations in the MAML1, EGR1 and p300 gene
set were associated with increased overall survival in renal clear
cell carcinoma. The genes encoding EGR1 (5q31.1) and CSF1R
(5q33–q35) have been reported as the most frequently altered
genes on chromosome 5 in renal cell clear carcinoma [22]. As the
MAML1 gene is located at 5q35.3, in close proximity to EGR1 and
CSFIR, we speculate that the MAML1 gene may be altered by
similar or the same mechanisms as EGR1 and CSF1R. Further
experiments will focus on elucidating whether the gene loci within
5q31–q35 are targets of altered epigenetic regulation in renal cell
clear carcinoma, which may result in altered expression of these
genes. Future in vivo studies will also be required to verify the
importance of the MAML1-EGR1 interaction in different cellular
contexts, and determine whether MAML1-dependent acetylation
of EGR1 play a role in tumorigenesis.
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Figure 5. Assessment of MAML1, EGR1 and p300 expression profiles in cancer tissues using the cBio Cancer Genomics Portal. (A)
Percentage of cancer cases with copy number alterations (x-axis), including amplification and homozygous deletions from 20 different cancer studies
(y-axis) (a total of 5134 samples). The number of assessed samples for each cancer type is indicated in brackets on the y-axis (B) Percentage of cancer
cases with copy number alterations in MAML1, EGR1 and p300 from 436 renal clear cell carcinoma samples; 31/436 cases displayed genomic
amplification in one or more of the selected gene triad. (C) Percentage of cases with mRNA level alterations in MAML1, EGR1 and p300 from 419 renal
clear cell carcinoma samples with available mRNA expression data; 69/419 cases displayed increased or decreased expression of one or more of the
selected gene triad. (D) Kaplan-Meier plot of overall survival for 419 kidney renal clear cell carcinoma patients, based on altered mRNA expression of
MAML1, EGR1 and p300. The patients were divided into two groups based on ‘‘alterations in the gene set’’ (n = 69) or ‘‘no alterations in the gene set’’
(n = 349). One sample was removed from the initial mRNA analysis due to missing survival data information. A significant difference in overall survival
was observed (p= 0.000356; log-rank test).
doi:10.1371/journal.pone.0046001.g005
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